198 related articles for article (PubMed ID: 8840003)
21. Measurements of the concentration of free plasminogen activator inhibitor (PAI-1) and its complex with tissue plasminogen activator in human plasma.
Takada Y; Takada A
Thromb Res Suppl; 1988; 8():15-22. PubMed ID: 3144765
[TBL] [Abstract][Full Text] [Related]
22. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
23. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
[TBL] [Abstract][Full Text] [Related]
24. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
25. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
26. Importance of plasminogen activator inhibitor type 1 (PAI-1) for preventing single chain urokinase plasminogen activator (scu-PA) conversion into two chain urokinase plasminogen activator (tcu-PA) in plasma in vitro.
Dosne AM; Dubor F; Samama M
Thromb Res; 1991 Sep; 63(5):531-9. PubMed ID: 1755005
[TBL] [Abstract][Full Text] [Related]
27. The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells.
Braat EA; Collen A; Jie AF; Grimbergen JM; Rijken DC
Biochim Biophys Acta; 2000 Sep; 1497(3):351-8. PubMed ID: 10996659
[TBL] [Abstract][Full Text] [Related]
28. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
29. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
[TBL] [Abstract][Full Text] [Related]
30. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
31. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
Lucore CL; Sobel BE
Circulation; 1988 Mar; 77(3):660-9. PubMed ID: 2449299
[TBL] [Abstract][Full Text] [Related]
32. Optimum conditions for the stabilization and measurement of tissue plasminogen activator activity in human plasma.
Chandler WL; Schmer G; Stratton JR
J Lab Clin Med; 1989 Mar; 113(3):362-71. PubMed ID: 2494279
[TBL] [Abstract][Full Text] [Related]
33. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
34. Clot lysis induced by a monoclonal antibody against alpha 2-plasmin inhibitor.
Sakata Y; Eguchi Y; Mimuro J; Matsuda M; Sumi Y
Blood; 1989 Dec; 74(8):2692-7. PubMed ID: 2510836
[TBL] [Abstract][Full Text] [Related]
35. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
36. [Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms].
Białkowska A; Kotschy M; Betlejewski S; Burduk D
Otolaryngol Pol; 1995; 49 Suppl 20():84-7. PubMed ID: 9454229
[TBL] [Abstract][Full Text] [Related]
37. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator.
van Griensven JM; Huisman LG; Stuurman T; Dooijewaard G; Kroon R; Schoemaker RC; Kluft K; Cohen AF
Clin Pharmacol Ther; 1996 Nov; 60(5):504-11. PubMed ID: 8941023
[TBL] [Abstract][Full Text] [Related]
38. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
[TBL] [Abstract][Full Text] [Related]
39. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
40. Interaction of single-chain urokinase and plasminogen activator inhibitor type 1.
Manchanda N; Schwartz BS
J Biol Chem; 1995 Aug; 270(34):20032-5. PubMed ID: 7544349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
